Lavender Essential Oil as Treatment for Chronic Migraine: A Protocol for Non-Inferiority Randomized Controlled Trial

Xiaocong Wang

doi:10.62051/ijphmr.v6n4.17

Authors

Xiaocong Wang

DOI:

https://doi.org/10.62051/ijphmr.v6n4.17

Keywords:

Chronic migraine, Lavender essential oil, Aromatherapy, Non-inferiority trial, Randomized controlled trial, Sumatriptan, Headache management

Abstract

This study is a randomized, investigator-blinded, controlled phase III clinical trial designed to compare the efficacy of daily atomized inhalation of lavender essential oil versus 50 mg sumatriptan tablets among Australians aged 18–65 years with chronic migraine, with a 3-month follow-up period. The primary outcome is the monthly reduction in headache days, defined as an improvement from moderate or severe pain to mild or no pain. Eligible participants diagnosed with chronic migraine by general practitioners and providing informed consent are randomized 1:1 to the intervention group (lavender essential oil) or the control group (sumatriptan tablets). This protocol aims to evaluate whether lavender essential oil is non-inferior to standard pharmaceutical treatment for chronic migraine management.

References

[1] K.R. Peck, Y.L. Johnson, T.A. Smitherman: Migraine. Handbook of Clinical Neurology, (2016), p.283–293.

[2] D.A. Economics: Migraine in Australia Whitepaper (Deloitte Access Economics Report, Australia 2018)

[3] ICHD-II Classification: Parts 1–3: Primary, Secondary and Other. Cephalalgia, Vol. 24 (2004) No.1_suppl, p.23–136.

[4] M.E. Bigal, D. Serrano, M. Reed, R.B. Lipton: Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology, Vol. 71 (2008) No.8, p.559–566.

[5] M.W. Weatherall: The diagnosis and treatment of chronic migraine. Therapeutic Advances in Chronic Disease, Vol. 6 (2015) No.3, p.115–123.

[6] T.J. Schwedt: Chronic migraine. BMJ, Vol. 348 (2014)

[7] S.D. Silberstein: Report of the Quality Standards Subcommittee of the American Academy of Neurology.

[8] M.J. Brown, P. Sharma, P.N. Bennett: Clinical Pharmacology (Elsevier, UK 2012).

[9] A. Olapour, K. Behaeen, R. Akhondzadeh: The effect of inhalation of aromatherapy blend containing lavender essential oil on cesarean postoperative pain. Anesthesiology and Pain Medicine, Vol. 3 (2013) No.1, p.203.

[10] Y.B. Yip, S.H. Tse: The effectiveness of relaxation acupoint stimulation and acupressure with aromatic lavender essential oil for non-specific low back pain. Complementary Therapies in Medicine, Vol. 12 (2004) No.1, p.28–37.

[11] R. Soltani, S. Soheilipour, V. Hajhashemi: Evaluation of the effect of aromatherapy with lavender essential oil on post-tonsillectomy pain in pediatric patients. International Journal of Pediatric Otorhinolaryngology, Vol. 77 (2013) No.9, p.1579–1581.

[12] S.H. Huang, L. Fang, S.H. Fang: The effectiveness of aromatherapy with lavender essential oil in relieving post arthroscopy pain. JMED Research, Vol. 2014 (2014), p.1–6.

[13] H.M. Cavanagh, J.M. Wilkinson: Lavender essential oil: a review. Australian Infection Control, Vol. 10 (2005) No.1, p.35–37

[14] L.W. Chien, S.L. Cheng, C.F. Liu: The effect of lavender aromatherapy on autonomic nervous system in midlife women with insomnia. Evidence-Based Complementary and Alternative Medicine, Vol. 2012 (2012)

[15] A.W. Chan, J.M. Tetzlaff, P.C. Gøtzsche: SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ, Vol. 346 (2013).

[16] NPS MedicineWise: Imigran tablets, https://www.nps.org.au/medicine-finder/imigran-tablets (2021)

[17] J.M. Lachin, J.P. Matts, L.J. Wei: Randomization in clinical trials: Conclusions and recommendations. Controlled Clinical Trials, Vol. 9 (1988) No.4, p.365–374.

[18] B. Aicher, H. Peil, B. Peil: Pain measurement: Visual Analogue Scale (VAS) and Verbal Rating Scale (VRS) in clinical trials with OTC analgesics in headache. Cephalalgia, Vol. 32 (2012) No.3, p.185–197

[19] P. Sasannejad, M. Saeedi, A. Shoeibi: Lavender essential oil in the treatment of migraine headache: a placebo-controlled clinical trial. European Neurology, Vol. 67 (2012) No.5, p.288–291.